Rocket Pharmaceuticals (RCKT) Cash from Financing Activities (2014 - 2026)

Rocket Pharmaceuticals has reported Cash from Financing Activities for 13 years, with the latest figure at -$1000.0 in Q1 2026.

• Quarterly Cash from Financing Activities changed N/A year-over-year to -$1000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $147000.0 (down 99.92% YoY) and the FY2025 annual result came in at $148000.0, down 99.92% from the prior year.
• Cash from Financing Activities rose to -$1000.0 in Q1 2026 per RCKT's latest filing, from -$67000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $189.5 million in Q3 2023 and troughed at -$67000.0 in Q3 2025.
• A 5-year average of $36.6 million and a median of $1.2 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities jumped 46664.45% in 2024, then sank 138.07% in 2025.
• Over 5 years, Cash from Financing Activities stood at $108.4 million in 2022, then tumbled by 99.64% to $391000.0 in 2023, then surged by 46664.45% to $182.8 million in 2024, then plunged by 100.04% to -$67000.0 in 2025, then soared by 98.51% to -$1000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$1000.0, -$67000.0, and $215000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.